Tag: evaluation

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

Explore the dynamic growth of the Drone Communication Market with the comprehensive Drone Communication Companies Quadrant report. Unveiling cutting-edge innovations and industry trends, the quadrant evaluates over 140 companies, spotlighting the top 15 leaders in advanced UAV communication technology. Key players like DJI, RTX, and Northrop Grumman are at the forefront, driving innovations such as BVLOS capabilities and SATCOM integration, empowering drones across defense, logistics, and emergency sectors. With a focus on secure data transmission and automation, the market is poised for transformative advancements. Discover how industry giants prioritize technological excellence and strategic growth in this evolving landscape.